Get the app
US › Healthcare

Boundless Bio, Inc. Common Stock (BOLD)

US · Healthcare · Biotechnology

$2.46+2.07%
Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-23.7M
EPS
$-1.06
EPS estimate
$-0.58

EPS came in at -1.06 against a street estimate of -0.58 — a miss of 82.8%.

Key statistics

Market cap
$55.9M
Forward P/E
0.0
P/B
0.84
Book value
$2.94
EPS (TTM)
$-2.85
52-week high
$3.16
52-week low
$0.96
50-day MA
$2.63
200-day MA
$1.93
Beta
0.46

Analyst view

Analysts rate Boundless Bio, Inc. Common Stock a hold (0 buy, 1 hold, 0 sell out of 1) with an average price target of $4.00.

Shareholding

Insiders
12.53%
Institutions
68.21%

Largest institutional holders

FundStake
ARCH VENTURE CORP11.66%
FMR Inc11.17%
TANG CAPITAL MANAGEMENT LLC11.08%
ADAR1 Capital Management LLC8.52%
Cormorant Asset Management, LLC4.33%
Vanguard Capital Management, LLC2.66%
Wellington Management Company LLP2.41%
Millennium Management LLC2.07%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Boundless Bio, Inc. Common Stock — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-11-07.